Dupilumab用于标准三联疗法难治性嗜酸性食管炎。

Revue medicale de Liege Pub Date : 2025-07-01
Rémi Gason, Jean-Baptiste Zeevaert, Floriane Ausloos, Fernand Weerts
{"title":"Dupilumab用于标准三联疗法难治性嗜酸性食管炎。","authors":"Rémi Gason, Jean-Baptiste Zeevaert, Floriane Ausloos, Fernand Weerts","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We report the case of a young man presenting with dysphagia and frequent food impactions, which led to the diagnosis of eosinophilic esophagitis based on endoscopic examination and confirmed anatomopathologically. Despite a triple therapy regimen including a high-dose proton pump inhibitor, an elimination of allergenic foods based on prick tests, and oral budesonide, there was no significant and sustained clinical or endoscopic improvement. In this context, through a compassionate use program, we initiated biotherapy with dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, which was recently approved for the treatment of refractory eosinophilic esophagitis by the European Medicines Agency. We report our experience over 6 months with this innovative treatment, which has been reimbursed in Belgium under certain conditions since November 1st, 2024.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 7-8","pages":"491-495"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Dupilumab for eosinophilic esophagitis refractory to standard triple therapy].\",\"authors\":\"Rémi Gason, Jean-Baptiste Zeevaert, Floriane Ausloos, Fernand Weerts\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We report the case of a young man presenting with dysphagia and frequent food impactions, which led to the diagnosis of eosinophilic esophagitis based on endoscopic examination and confirmed anatomopathologically. Despite a triple therapy regimen including a high-dose proton pump inhibitor, an elimination of allergenic foods based on prick tests, and oral budesonide, there was no significant and sustained clinical or endoscopic improvement. In this context, through a compassionate use program, we initiated biotherapy with dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, which was recently approved for the treatment of refractory eosinophilic esophagitis by the European Medicines Agency. We report our experience over 6 months with this innovative treatment, which has been reimbursed in Belgium under certain conditions since November 1st, 2024.</p>\",\"PeriodicalId\":94201,\"journal\":{\"name\":\"Revue medicale de Liege\",\"volume\":\"80 7-8\",\"pages\":\"491-495\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale de Liege\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale de Liege","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

我们报告一个年轻男性的情况下,表现为吞咽困难和频繁的食物嵌塞,导致诊断嗜酸性粒细胞食管炎基于内镜检查和病理解剖证实。尽管采用了三联治疗方案,包括高剂量质子泵抑制剂、基于点刺试验消除致敏食物和口服布地奈德,但临床或内窥镜检查没有显著和持续的改善。在这种情况下,通过慈悲使用计划,我们启动了dupilumab的生物治疗,dupilumab是一种靶向白细胞介素4和白细胞介素13受体的单克隆抗体,最近被欧洲药品管理局批准用于治疗难治性嗜酸性粒细胞性食管炎。我们报告了我们使用这种创新治疗超过6个月的经验,自2024年11月1日起,在某些条件下,我们已经在比利时报销了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Dupilumab for eosinophilic esophagitis refractory to standard triple therapy].

We report the case of a young man presenting with dysphagia and frequent food impactions, which led to the diagnosis of eosinophilic esophagitis based on endoscopic examination and confirmed anatomopathologically. Despite a triple therapy regimen including a high-dose proton pump inhibitor, an elimination of allergenic foods based on prick tests, and oral budesonide, there was no significant and sustained clinical or endoscopic improvement. In this context, through a compassionate use program, we initiated biotherapy with dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, which was recently approved for the treatment of refractory eosinophilic esophagitis by the European Medicines Agency. We report our experience over 6 months with this innovative treatment, which has been reimbursed in Belgium under certain conditions since November 1st, 2024.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信